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apnoea
Key Messages
1. We have validated a Chinese version 
of the Sleep Apnoea Quality of Life 
Index, a disease-specific health-
related quality of life (HRQOL) 
instrument, for use in health care 
research of obstructive sleep apnoea 
(OSA) in a Cantonese-speaking 
Chinese population. This instrument 
may be further adapted to suit Chinese 
populations whose main dialect is not 
Cantonese.
2. For treatment of mild and moderate 
OSA, using nasal continuous positive 
airway pressure or an oral appliance 
(OA) in addition to weight control 
will achieve improvements in terms of 
sleep parameters, daytime sleepiness, 
and HRQOL.
3. Continuous positive airway pressure 
is superior to OAs with respect to the 
first two parameters, but similar to OA 
in terms of HRQOL improvement.
4. For the treatments of mild and 
moderate OSA, lifestyle modification 
measures, in particular weight 
reduction, should be implemented 
for all overweight patients. However, 
only about half of them will achieve 
a degree of weight reduction over 10 
weeks and associated reduction of 
sleep-disordered breathing events, 
and even then control of such events 
is usually incomplete.
5. Factors other than treatment 
effectiveness as demonstrated by 
physiological and neurobehavioural 
outcome measures affect the patient’s 
choice of treatment modality; 
such factors include subjective 
considerations, convenience, and 
cost.
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Introduction
Obstructive sleep apnoea (OSA) affects 2 to 4% of the middle-aged Caucasian 
population as well as Chinese inhabitants of Hong Kong.1 Criteria for treatment 
of OSA are based on symptoms and physiological severity. Various treatment 
options have their own benefits and limitations.2 In severe OSA, application of 
nasal continuous positive airway pressure (CPAP) has been shown to be safe and 
effective as judged by various outcome measures, but the optimal management 
for those with milder OSA is more controversial. Apart from CPAP, other non-
surgical options include oral appliances (OAs) and lifestyle modification.
Aims and objectives
This study aimed to produce a validated disease-specific health-related quality 
of life (HRQOL) instrument for use as an outcome measure in sleep apnoea in 
Chinese, and to evaluate the effectiveness of treatments (lifestyle modification 
alone vs addition of CPAP or an OA) in patients with mild or moderate sleep 
apnoea.
Methods
This study was conducted from September 1999 to March 2002.
Validation of the Chinese version of the Sleep Apnoea Quality of Life 
Index
The Sleep Apnoea Quality of Life Index (SAQLI) originally developed and 
validated in an English-speaking population,3 was translated into Chinese.4 The 
translated version was applied to OSA subjects for assessment of its acceptability, 
scaling assumptions, reliability, validity, and responsiveness.
Randomised controlled study of treatment of mild and moderate 
obstructive sleep apnoea
Patients were recruited from the Department of Medicine, Queen Mary Hospital 
and Department of Medicine, Pamela Youde Nethersole Eastern Hospital.5 
Inclusion criteria were age >21 to 70 years, and the diagnosis of mild-to-
moderate OSA was based on the following criteria: apnoea-hypopnoea index 
(AHI) ≥5 to 20 with Epworth sleepiness scale (ESS) score >9, or AHI >20 to 40. 
Exclusion criteria were other unstable medical diseases, ‘dangerous’ sleepiness, 
coexistence of sleep disorders other than OSA, previous surgery to the upper 
airway (excluding the nose), and pregnant women.
 Patients were randomised to the following three arms of treatments for 
10 weeks: (1) control group—only conservative measures (CM) of lifestyle-
behavioural modification, (2) CPAP+CM group—use of nasal CPAP in addition 
to CM, and (3) OA+CM group—use of OA in addition to CM. Conservative 
management included advice on measures that help to decrease sleep apnoea. 
Those who were overweight were referred to a weight reduction programme. 
Those randomised to CPAP were advised to use it at a pre-titrated pressure 
every night during sleep; while those randomised to the OA were referred to an 
orthodontist in Prince Philip Dental Hospital for fabrication of the appliance and 
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to use it every night during sleep.
 For the purpose of evaluation, the primary outcome 
indicator was daytime sleepiness: ESS score, and the 
secondary outcome indicator was the HRQOL. These 
parameters were obtained at baseline and at 10 weeks. For 
those who were on CPAP and OA, polysomnography (PSG) 
was repeated after taking off the device for 1 week to assess 
for changes related to lifestyle modification rather than the 
device.
 Evaluation instruments were: (1) PSG (Alice 3/4 
system, Respironics, Atlanta, US) recording sleep stages, 
oxygen saturation, airflow, respiratory movements, etc; (2) 
symptoms—questionnaire on sleep apnoea symptoms and 
the ESS; (3) the HRQOL—Chinese version of short-form 
health survey questionnaire (SF-36) and SAQLI; and (4) 
blood pressure. Side-effects of treatment and adherence to 
therapy were also assessed at 10 weeks. On completion of 
study, patients were asked if they would choose to continue 
on the treatment to which they were randomised, and any 
reasons for discontinuation.
Results
Validation of the Chinese version of Sleep Apnoea 
Quality of Life Index
A cross-sectional sample of 106 Chinese OSA patients and a 
longitudinal sample of 51 patients in Hong Kong completed 
the Chinese (Cantonese) version of SAQLI.4 The instrument 
was understood and perceived as relevant by 97% of the 
subjects. Internal consistency, test-retest reliability, item-
scale convergent validity and discriminatory validity, and 
construct validity were good to excellent. Construct validity 
was confirmed by significant correlations with SF-36 
subscale scores. However, factor analysis showed that only 
items of daily functioning and symptom domains all loaded 
on the hypothesised scales. Longitudinal data showed that 
SAQLI was more responsive than SF-36 to changes after 
treatment.
Effectiveness of three treatment modalities
101 subjects were randomised to one of the three treatment 
groups. Ten subjects withdrew: four subjects in OA group 
had gum problems, one in the CPAP group had intolerance 
of the device, and five in the CM group refused to undergo 
PSG at 10 weeks. There was no significant difference 
between baseline parameters in those who completed the 
study and those who did not.
 General advice on sleep hygiene was given to all 
subjects. Eighty-four subjects were overweight/obese 
and were referred for weight control programme. 
However, significant weight loss was only observed in 
the CPAP group. In all, 45 subjects had a decrease in body 
weight (15 subjects in each of the three groups) from a 
mean±standard deviation (SD) of 76±11 to 73±10 kg.
Their AHI decreased from a mean±SD of 25±12 to 19±14. 
Eight subjects (mean AHI=15 at baseline) had a mean 
AHI of <5 after weight reduction, while the others still 
had an AHI of ≥5.
Symptoms and physiological parameters
Regarding daytime sleepiness, compared with baseline 
values, ESS decreased significantly in all three treatment 
arms although the post-treatment ESS of the CM group 
was still above the norm (defined as >9). The differences 
between the mean change in ESS of the CM+CPAP and 
CM only groups, and between the CM+CPAP and CM+OA 
groups were statistically significant.
 Regarding sleep study parameters, the AHI of subjects 
in both CPAP and OA groups decreased significantly 
compared to their baseline values, but only subjects assigned 
to CPAP achieved AHI values of <5, the commonly used 
threshold criterion for OSA. Subjects in the CM group did 
not yield any change in AHI after 10 weeks. Changes in 
AHI were significantly different among the three groups; 
the CPAP+CM group showed the largest decrease.
 There was no statistically significant difference in 
changes in blood pressure among the three treatment groups, 
although there were reductions in post-treatment morning 
diastolic blood pressure compared to baseline in the CPAP 
and OA groups.
Health-related quality of life
At baseline, the scores of several SF-36 domains were 
lower than that of the local population norm. After the 
CPAP+CM treatment, all affected domains of the SF-
36 were restored to normal, except for social functioning 
and mental health; while the scores for social functioning 
and bodily pain domains of the OA+CM group, as well as 
those for role-physical, social functioning, bodily pain and 
physical functioning of the CM group remained lower than 
the respective population norms. The CPAP was better than 
OA or CM in terms of the magnitude of the response in 
bodily pain, and better than CM with respect to the treatment 
response for physical functioning.
 The SAQLI scores in both CPAP and OA groups 
increased significantly compared to their baseline values. 
The CPAP+CM group showed improvement in all four 
domains while OA+CM group improved in three domains, 
but not ‘social interaction’; the CM group showed no 
significant change in any domain.
 The increase in SAQLI scores in both the CPAP+CM 
and OA+CM groups were significantly better than that of 
CM group. Only if treatment-related symptoms (domain 
E) were not included, did the CPAP group show more 
improvement than in the OA group.
Side-effects of treatment and compliance
All subjects in CPAP group reported some side-effects, 
including dryness of nose/mouth/throat, feeling of pressure, 
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noise from machine, and facial skin abrasion. The mean 
CPAP use was 4.4 nights per week and 4.2 hours per night. 
Side-effects experienced with the OA included excessive 
salivation, temporomandibular joint discomfort, dryness of 
throat, and teeth discomfort. All side-effects were considered 
as mild. Mean self-reported use of the device was 5.2 nights 
per week and 6.4 hours per night. No particular side-effects 
related to lifestyle modification measures were reported.
Patient choice of treatment
At the end of the study, 50% of the CPAP+CM group, 
80% of OA+CM group, and 70% of CM group chose to 
continue with the assigned treatment instead of changing 
to another option. The reasons for doing so in CPAP and 
OA groups were perceived benefits from the treatment they 
were receiving, while the main reason for the CM group 
was the convenience.
Discussion
In patients with mild or moderate OSA, symptom relief and 
improving quality of life are important outcome measures as 
the long-term morbidity has not been established. Our study 
was designed to compare the three most commonly used 
treatment modalities regarding their effects on symptoms, 
health status, and physiological parameters in subjects with 
mild and moderate OSA.
 Our study found that CPAP was more effective than OA 
in eliminating respiratory events during sleep, similar to 
that of previous studies, while patients on CM alone had no 
significant change in AHI. Subjective sleepiness measured 
by ESS improved in all three treatment arms, although those 
treated conservatively still had excessive daytime sleepiness 
as reflected by post-treatment ESS of >9. The improvement 
of ESS score was significantly greater in CPAP+CM group 
than OA+CM and CM groups, suggesting that only CPAP 
effectively improved the symptom of daytime sleepiness.
 It is well-documented that the quality of life of severe 
OSA patients is impaired, and CPAP, compared with 
placebo, can improve their quality of life. For patients with 
milder disease, whether CPAP can improve quality of life 
is unclear. We found that both CPAP and OA can improve 
quality of life in these OSA subjects, while CM alone has 
no beneficial effect. Side-effects due to treatment were 
more common in the CPAP group, and this has an impact 
on HRQOL as evidenced by the SAQLI assessment which 
showed a nullification of the superiority of CPAP over OA 
when treatment-related symptoms were included.
 Overweight OSA patients are usually advised to lose 
weight. No randomised controlled trial has been performed 
for this commonly used treatment in OSA, but several open 
studies have shown improvement or deterioration of OSA 
with weight change. Although the CM group failed to show 
any significant change in body mass index or AHI, when we 
examined the entire study sample, subjects who could lose 
weight enjoyed an improvement in AHI. However, weight 
reduction was achieved in only about half of the overweight 
subjects, and less than 10% could achieve enough weight 
loss to result in a normal sleep breathing status of AHI <5. 
Addition of the device appeared to facilitate weight loss.
 Although the CPAP+CM group showed the greatest 
improvement in physiological and neurobehavioural 
outcome measures, the lowest proportion of patients chose 
to continue this form of treatment suggesting that choice of 
treatment modality was not solely based on effectiveness 
of the treatment. Considerations of convenience, cost, and 
other factors may also influence choice. However, this 
study was not a cross-over study, so personal experience of 
all options in an individual was not available for decision-
making.
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